公开(公告)号：US20240279602A1

公开(公告)日：2024-08-22

申请号：US18569736

申请日：2022-06-16

申请人： Kyoto University ,  Sumitomo Pharma Co., Ltd.

发明人： Jun TAKAHASHI ,  Daisuke DOI ,  Megumi IKEDA

IPC分类号： C12N5/0793 ,  A61K35/30 ,  C12Q1/68

CPC分类号： C12N5/0619 ,  A61K35/30 ,  C12Q1/68 ,  C12N2500/38 ,  C12N2501/01 ,  C12N2501/13 ,  C12N2506/45

摘要： The present disclosure provides a cerebral organoid derived from a human pluripotent stem cell, a cell aggregate including a cerebral cortical cell, and a method for producing any of them, each being useful for regenerative therapy.

公开(公告)号：US20240252544A1

公开(公告)日：2024-08-01

申请号：US18290392

申请日：2022-05-13

申请人： RIKEN ,  Sumitomo Pharma Co., Ltd.

发明人： Michiko Mandai ,  Suguru Yamasaki

IPC分类号： A61K35/30 ,  C12N5/079

CPC分类号： A61K35/30 ,  C12N5/0618 ,  C12N2501/155 ,  C12N2501/727 ,  C12N2506/02 ,  C12N2513/00 ,  C12N2533/52

摘要： An object of the present invention is to provide a method for producing a retinal cell or retinal tissue with a reduced proportion of non-target cells in differentiating pluripotent stem cells. The method of the present invention for producing a retinal cell or retinal tissue comprises: (A) suspension-culturing a pluripotent stem cell to form a cell aggregate of pluripotent stem cells; and (B) suspension-culturing the cell aggregate obtained in the step (A) in the presence of a BMP signaling pathway agonist and a CHK1 signaling pathway inhibitor to obtain a cell aggregate containing a retinal cell.

公开(公告)号：US20240150370A1

公开(公告)日：2024-05-09

申请号：US18506804

申请日：2023-11-10

申请人： Sumitomo Pharma Co., Ltd.

发明人： Satoshi ADACHI ,  Hidefumi YOSHINAGA ,  Hajime SHIBATA ,  Yusuke SHIODA ,  Riko NAGAHAMA

IPC分类号： C07D491/048 ,  A61P25/00 ,  C07D213/65 ,  C07D215/12 ,  C07D221/04 ,  C07D401/06 ,  C07D471/04 ,  C07D495/04

CPC分类号： C07D491/048 ,  A61P25/00 ,  C07D213/65 ,  C07D215/12 ,  C07D221/04 ,  C07D401/06 ,  C07D471/04 ,  C07D495/04

摘要： The present disclosure provides bicyclic pyridine derivatives.
A compound represented by formula I:




or a pharmaceutically acceptable salt thereof,

wherein



X is a oxygen atom, sulfur atom, NR, or CR′R″, n is 0 or 1, R1, R2a, R2b, R2c, R2d, R, R′ and R″ are each independently a hydrogen atom, a halogen atom, optionally substituted C1-6 alkyl, or an optionally substituted C6-10 aryl, or two of R2a, R2b, R2c, R2d, R, R′, and R″, together with a carbon atom or a nitrogen atom to which they are attached, form a 3- to 6-membered saturated carbocyclic ring or saturated heterocyclic ring, and R3a, R3b, R3c and R5a and R5b, are as defined in the description.

公开(公告)号：US20240122941A1

公开(公告)日：2024-04-18

申请号：US18258989

申请日：2021-12-24

申请人： NATIONAL CANCER CENTER ,  Sumitomo Pharma Co., Ltd.

发明人： Hideaki OGIWARA ,  Mariko SASAKI

IPC分类号： A61K31/553 ,  A61K31/405 ,  A61K31/415 ,  A61K31/4172 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/426 ,  A61K31/431 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/675 ,  A61P35/00 ,  C12N9/10 ,  C12N9/99

CPC分类号： A61K31/553 ,  A61K31/405 ,  A61K31/415 ,  A61K31/4172 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/421 ,  A61K31/426 ,  A61K31/431 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/675 ,  A61P35/00 ,  C12N9/1025 ,  C12N9/99

摘要： The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the formulae are as set forth in the specification) or a pharmaceutically acceptable salt thereof can have a therapeutic and/or prophylactic effect on SWI/SNF complex-dysfunction cancer. A pharmaceutical composition, which is for treating and/or preventing cancer and contains a CBP/P300 inhibitor, can be provided. The cancer may be SWI/SNF complex-dysfunction cancer. The SWI/SNF complex-dysfunction cancer may be BAF complex-dysfunction cancer. The BAF complex-dysfunction cancer may be SMARC-deficient cancer, ARID-deficient cancer, or SS18-SSX fusion cancer. The SMARC-deficient cancer may be SMARCB1-deficient cancer, SMARCA2-deficient cancer, SMARCA4-deficient cancer, or SMARCA2/A4-deficient cancer.

公开(公告)号：US20240119684A1

公开(公告)日：2024-04-11

申请号：US18545187

申请日：2023-12-19

申请人： Pixie Dust Technologies, Inc. ,  Sumitomo Pharma Co., Ltd.

发明人： Megumi TABATA ,  Haruki NISHIMURA ,  Akira ENDO ,  Yasuhiro HABARA ,  Masaki GOMI ,  Yudai TAIRA

IPC分类号： G06T19/00 ,  G02B27/01 ,  G10L15/26 ,  H04R1/32

CPC分类号： G06T19/006 ,  G02B27/017 ,  G10L15/26 ,  H04R1/32 ,  G02B2027/0178

摘要： A display control apparatus for controlling display of a display device acquires speech collected by a plurality of microphones and estimates a sound-arrival direction of the acquired speech. Then, the display control apparatus causes a text image corresponding to the acquired speech to be displayed in a predetermined text display area in a display unit of the display device, and causes a symbol image associated with the text image to be displayed at a display position in the display unit, the display position corresponding to the estimated sound-arrival direction.

公开(公告)号：US11911466B2

公开(公告)日：2024-02-27

申请号：US17583933

申请日：2022-01-25

申请人： Sumitomo Pharma Co., Ltd.

发明人： Hidenori Kimura ,  Hitoshi Ban ,  Yoshiaki Isobe ,  Hitoshi Watanabe

IPC分类号： C07D239/49 ,  A61K39/39 ,  A61K39/00 ,  A61P37/04

CPC分类号： A61K39/39 ,  A61K39/00 ,  A61P37/04 ,  C07D239/49 ,  A61K2039/505

摘要： The present invention provides a compound of the formula (1):




wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.

公开(公告)号：US20240032850A1

公开(公告)日：2024-02-01

申请号：US18038646

申请日：2021-11-26

申请人： Sumitomo Pharma Co., Ltd.

发明人： Yasushi Ochiai ,  Kazuki Kasai

IPC分类号： A61B5/00 ,  A61B5/16 ,  G16H50/30

CPC分类号： A61B5/4064 ,  A61B5/7425 ,  A61B5/163 ,  A61B5/162 ,  G16H50/30 ,  A61B2560/02

摘要： The present disclosure provides an evaluation device for evaluating a test subject's ability to identify an object, the evaluation device including: an input unit that receives input of the test subject; a display control unit that displays, on a display device, a test screen including a target object that the test subject should select and a non-target object that the test subject should not select; an input processing unit that determines whether or not a target object is selected on the basis of input of the test subject received by the input unit; and an evaluation unit that evaluates a temporal lobe function related to a visual recognition ability of the test subject on the basis of a response time required for the test subject to input when the input processing unit determines that the target object is selected.

公开(公告)号：US20230404451A1

公开(公告)日：2023-12-21

申请号：US18248181

申请日：2021-10-06

申请人： NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY ,  Sumitomo Pharma Co., Ltd.

发明人： Toshiya NAKAGUCHI ,  Eiji SHIMIZU ,  Yoshiyuki HIRANO ,  Chihiro SUTOH ,  Naomi SHIRAIWA ,  Yuki IKEDA ,  Shunsuke SAITO

IPC分类号： A61B5/16 ,  A61B5/00 ,  G06T7/70 ,  G06T7/00 ,  G16H20/70

CPC分类号： A61B5/163 ,  A61B5/165 ,  A61B5/4836 ,  G06T7/70 ,  G06T7/0012 ,  G16H20/70 ,  G06T2207/30201 ,  G06T2207/30004

摘要： A sightline-position determination device includes: a sightline-position input unit to which a position of a sightline of a user is inputted; a determination region setting unit which sets a determination region; a determination unit which determines whether or not the position of the sightline inputted from the sightline-position input unit falls within the determination region; and an output unit which outputs feedback to the user when the determination unit has determined that the position of the sightline falls within the determination region.

公开(公告)号：US11833247B2

公开(公告)日：2023-12-05

申请号：US17570635

申请日：2022-01-07

申请人： Sumitomo Pharma Co., Ltd.

发明人： Akihisa Fukushima

IPC分类号： A61K9/127 ,  A61K47/69 ,  A61K47/54 ,  A61K31/505 ,  A61K39/39 ,  A61K47/24 ,  A61K47/28 ,  A61K45/06

CPC分类号： A61K9/127 ,  A61K31/505 ,  A61K39/39 ,  A61K47/24 ,  A61K47/28 ,  A61K47/54 ,  A61K47/69 ,  A61K45/06

摘要： The present invention provides a liposome useful as a vaccine adjuvant. More specifically, the present invention provides a liposome which comprises a lipid bilayer comprising dimyristoylphosphatidylcholine and egg phosphatidylglycerol and a conjugated compound in which a low-molecular weight compound enhancing the physiological activity of TLR7 is bound to squalene via a linker, said conjugated compound being encapsulated in the lipid bilayer.

公开(公告)号：US20230298707A1

公开(公告)日：2023-09-21

申请号：US18120967

申请日：2023-03-13

申请人： Sumitomo Pharma Co., Ltd.

发明人： Julia Hyde GRAY ,  Mingzhe TAO

IPC分类号： G16H10/20

CPC分类号： G16H10/20

摘要： A computer-implemented method for clinical trial results endpoint-based analysis and dynamic aggregation, comprising the steps of receiving one or more selected clinical trials, wherein the one or more selected clinical trials match a specification; obtaining clinical trial results for the one or more selected clinical trials from at least one external data source; and interpreting, via a machine learning model, the obtained clinical trial results; importing the obtained clinical trial results as structured data. The method further comprising the steps of matching, based on a similarity analysis, via a processor, clinical trial endpoints identified in the obtained clinical trial results to corresponding normalized endpoint options; aggregating, based on the matched corresponding normalized endpoint options, the obtained clinical trial results to determine aggregated results; and providing the aggregated results.